On Nov. 20, join the call! Today we announced that Recursion and Exscientia shareholders have approved the proposed business combination. On Wed., Nov. 20, 7:30am ET / 5:30am MT / 12:30pm GMT, we’re holding a special update call to discuss the next chapter of Recursion after the planned close of our business combination. This is a pivotal moment for both Recursion and for the TechBio industry – bringing together two industry-leading pipelines, significant therapeutic discovery partnerships with leading pharma companies, and automated, AI-enabled platforms in biology and precision chemistry. ?? The update call will be livestreamed on LinkedIn, or tune in on:? ? X: https://lnkd.in/gn52iH5F Or ? YouTube: https://lnkd.in/gNx66QJK ? Submit your questions here either prior to – or during – the livestream: https://lnkd.in/evTuuskj ?? Learn more: https://lnkd.in/ehZE4-F7
Recursion的动态
最相关的动态
-
Be sure to catch Wheeler's Chief Development Officer Brian R. Berquist, Ph.D. on ATUM's latest webinar where they will be taking a deep dive into many of the technologies, methods, and models that we utilize to ameliorate the translational gap in biologics development. #webinar #biologics #discovery
?? Don't miss ATUM's upcoming webinar with Wheeler Bio, Inc. exploring innovative strategies for biologics discovery and development! Discover how leveraging cutting-edge tools, technologies, and machine learning can overcome scaling-up hurdles. Learn from Oren Beske, Ph.D., Amalgamator of Business & Biology at ATUM, and Brian R. Berquist, Ph.D., Chief Development Officer at Wheeler Bio, about the combined use of an open-source platform and hybrid-mechanistic process model, enabling well-controlled SBCs, high titers, and process robustness. Understand the benefits of SBC-based platforms in reducing early development costs and timelines. ?? REGISTER HERE: https://hubs.li/Q02sBs630 #ClinicalDevelopment #PreClinical #BiologicsManufacturing #CellAndGeneTherapies
-
Check out our upcoming webinar ?? #Revvity and #Tanvex will discuss high throughput methods to accelerate the development of advanced biotherapeutics Hear how Revvity is helping tackle the development of complex bispecific antibodies using the #CHOSOURCE expression platform and the #LabChip protein characterization system
Join our live webinar hosted by Drug Discovery World on how high-throughput bioanlytical methods can accelerate your biotherapeutic workflows with Ron Morena, Tanvex CDMO, and Neha Mishra, Revvity. Register today https://ms.spr.ly/6042YBbC0
Webinar: Higherthroughput bioanalytical methods accelerate the development and evaluation of advance biotherapeutics
register.gotowebinar.com
-
XtalPi's drug discovery capabilities streamline every step, from library design and synthesis to compound delivery. In these two new case studies, our team shares how we accomplished this rapidly (in less than a week) for recent projects. Click here to read the case studies now: https://hubs.li/Q02yYyTg0 #librarysynthesis #compounddelivery #librarydesign #drugdiscovery
-
-
?? Check out this free Toronto Research Chemicals #infographic on fragment-based drug discovery #FBDD ???? It covers key discoveries, clinical pipeline, library design principles, and fascinating case studies. Download it now!? https://okt.to/kTtXws #DrugDiscovery #AnalyticalChemistry
Free Infographic | Download Now!
www2.lgcgroup.com
-
What's the most impactful or misleading advice you've encountered in your career? Join us for this Pharma's Almanac roundtable, where a panel of industry experts delve into the conventional wisdom they believe is outdated, misguided, or simply incorrect. Read the full roundtable here: https://lnkd.in/eTsQ4qj9 Our roundtable features contributors from Vectron Biosolutions AS, Alconox Inc., PPD, Dynamk Capital, Mikart, LLC, Tanvex CDMO, Scorpius BioManufacturing, Inc., Envisagenics, Qualtrics, Astrea Bioseparations, Charles River Laboratories, Epocrates Inc, eClinical Solutions, Rentschler Biopharma, Be The Match BioTherapies, MMIT (Managed Markets Insight & Technology), Catalent Pharma Solutions, LabVantage Solutions, Inc, Personalis, Inc., Rune Labs, Mission Bio, VintaBio, BioCina, Center for Breakthrough Medicines, Alto Neuroscience, Elixirgen Therapeutics, Inc., Seer, Karius, Opentrons Labworks Inc., Rani Therapeutics, OM1, Inc., BIOSENIC S.A., eXmoor Pharma, BioBridge Global, Terumo Blood and Cell Technologies, TrakCel, ScaleReady, Ori Biotech... (cont) #Biopharma #Insights #Pharma #Roundtable
-
-
The Oligo Analysis Accelerator (OAA) for OpenLab CDS 2 is now available – a powerful software add-on designed for QC analysis of oligonucleotide therapeutics using LC/MS technology. Developed for late-stage pharma and biopharma, OAA offers an intuitive interface to streamline data processing acquired from our industry-leading LC/MSD XT hardware. Key benefits include: ? Faster Analytical Workflows: Reduce time-on-task from days to just hours. ? Improved Data Quality: Automated peak integration and spectrum interpretation, eliminating manual errors. ? Scalable Architecture: Easily supports growing data processing needs in client-server environments. This innovation helps optimize oligo QC workflows and enhance lab productivity. #OligoTherapeutics #LabInformatics #LCMS #PharmaInnovation #OpenLab #DataProcessing #Biopharma
-
Delivering insight, showing how Waters biopharmaceutical analytical solutions can help you advance your science
Attending PEGS Europe in November? Join me in the Exhibit Hall on November 6th for an insightful presentation and lunch. Developing safe and efficacious biotherapeutics requires robust analytical measurement. LC-MS and multi-angle light scattering (MALS) are established tools for characterization and monitoring. LC-MS generates structural data, providing insights into attributes throughout development and manufacture. MALS determines the size, aggregation, and conformation state of therapeutics. With the digital integration of LC, these techniques are ready to support work in both regulated and non-regulated labs. They enhance selectivity, resolution, and throughput, aiding analysis with compliance-ready connectivity. Don’t miss this opportunity to learn how these advanced tools can streamline your workflows! #Biotherapeutics #AnalyticalChemistry #LCMS #MALS https://lnkd.in/e2UCgHct
-
Curious about what's inside the new Simcyp? Simulator version 23? Don't miss this exclusive webinar, "What’s New in the Simcyp? Simulator – From Regulatory Advances to New Modalities.” ? Explore the latest features designed to revolutionize drug development: ? ? Addressing new regulatory guidance ? Expansion of biologics capabilities ? Advancements in virtual bioequivalence ? New mechanistic models for long-acting injectables ? Register now: https://ow.ly/knfQ50QOY04 ? #PBPK #DrugDevelopment #RegulatoryAdvances #Webinar #Simcyp #SimcypSimulator #Webinar
What’s New in the Simcyp? Simulator - from Regulatory Advances to New Modalities
https://www.certara.com
-
New look, new solutions. Have you seen our new Biopharma and Pharma web pages? Our new drug discovery research page has you covered from biomarker discovery, to #Met ID and #PROTACs. Learn more https://bit.ly/3RkS0dV #DrugDiscovery #BiomarkerDiscovery #HTS
Drug discovery research | SCIEX
sciex.com
-
New look, new solutions. Have you seen our new Biopharma and Pharma web pages? Our new drug discovery research page has you covered from biomarker discovery, to #MetID and #PROTACs. Learn more https://bit.ly/3RkS0dV #DrugDiscovery #BiomarkerDiscovery #HTS
Drug discovery research | SCIEX
sciex.com
